Introduction
The American Cancer Society estimates that 63 210 new cases of bladder cancer will be diagnosed this year in the US and about 13 180 people will die of the disease (overview: Bladder cancer, ACS, 2005: http://www.cancer.org). Although most bladder cancers are superficial at initial diagnoses, they have a high rate of recurrence and the prognosis for patients with advanced bladder cancer is poor.
1,2 Therefore, novel treatments could significantly improve the outcome for bladder cancer patients.
Numerous investigators have reported on gene therapy using adenovirus as a treatment strategy for cancer. Bladder cancer may be more amenable to gene therapy than other cancers. First, the bladder is easily accessible by noninvasive means. Second, instillation of adenovirus into the bladder is well tolerated and does not result in systemic dissemination. 3 Third, in an animal model the protective glycosamine glycan layer of the bladder was reduced in areas of tumors, suggesting that malignant cells may be more easily transduced by adenovirus than the normal bladder epithelium. 4 The Ad5 serotype, the most common adenoviral gene therapy vector, enters cells by binding of the fiber knob to the coxsackie-adenovirus receptor (CAR), which is followed by internalization, endocytosis and transport to the nucleus where gene expression occurs. 5 Tumor necrosis factor related apoptosis-inducing ligand (TRAIL/Apo2L) is a member of the TNF superfamily that can induce apoptosis by binding to its corresponding cell surface receptors. 6 In contrast to other members of the TNF superfamily, TRAIL is well tolerated in mice and nonhuman primates [7] [8] [9] and a Phase I clinical trial has recently been initiated. TRAIL induces apoptosis by binding to the death domain containing receptors DR4 and DR5 followed by activation of the initiator caspase-8. Caspase-8 either in a mitochondriadependent (via caspase-9) or -independent pathway activates caspases-3 and -7 that are responsible for the execution phase of apoptosis. The apoptotic pathway is negatively regulated by antiapoptotic proteins such as cFLIP, Mcl-1, Bcl-X L , and XIAP, which inhibit caspases or proapoptotic members of the Bcl-2 family.
We have shown that infection with an adenovirus expressing full-length membrane-bound TRAIL (Ad-TRAIL) can induce apoptosis in prostate cancer cells that are resistant to soluble recombinant TRAIL. 10 In this study, we investigated the in vitro efficacy of AdTRAIL in two bladder cancer cell lines, 5637 and T24. AdTRAIL induced apoptosis more effectively in 5637 cells than in T24 cells, a difference that was related to infectivity and transgene expression due to low CAR expression on T24 cells. The histone deacetylase inhibitor (HDACi) Trichostatin A (TSA) restored CAR expression and increased efficacy of AdTRAIL gene therapy. In addition, TSA reduced expression of the antiapoptotic proteins cFLIP and Bcl-X L . Overexpression of cFLIP reversed sensitization by TSA, indicating the importance of this protein during TSA-mediated sensitization to TRAIL. Our data suggests that bladder cancer may be treated by AdTRAIL gene therapy and that combination with TSA can enhance efficacy, particularly in tumors with downregulated CAR expression.
Materials and methods

Cell lines
The bladder cancer cell lines 5637 and T24 were purchased from the American Type Culture Collection (Rockville, MD), cultured in Primaria plasticware (Falcon, Bedford, MA) and propagated in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with heat-inactivated 10% fetal bovine serum (Hyclone, Logan, UT). Cells were maintained at 371C in a 5% CO 2 atmosphere. Plasmids encoding cFLIP-GFP fusion proteins were a gift from Dr Harald Wajant (University of Stuttgart, Germany).
11 DNA was prepared using the Endo-Free kit (Qiagen Inc, Valencia, CA) linearized with DraIII (New England Biolabs, Beverly, MA) and transfected using Lipofectamine Plus (Invitrogen). At 48 h post-transfection, cells were plated into selective media containing 600 mg/ml G418. Individual colonies were screened for GFP expression by flow cytometry and Western blot for expression of the fusion protein.
Viral vectors
The adenoviral vectors AdGFP and AdTRAIL have been described and characterized previously. 10 The viral particles were 5.3 Â 10 12 per ml and 7.8 Â 10 12 per ml for AdGFP and AdTRAIL, respectively. Constructs were titered by counting GFP positive cells expressed as infectious units/ml (IU/ml). The preparations used in this manuscript were 2 Â 10 12 (vp/IU ratio 2.65) and 2 Â 10
10
(vp/IU ratio 390) for AdGFP and AdTRAIL, respectively.
Apoptosis and viability assays
For the CellTiter s Aqueous One Solution Cell Proliferation (MTS) assay and the Apo-ONEt homogeneous caspase-3/-7 assay (both from Promega, Madison, WI), cells were seeded into 96-well plates at 1 Â 10 4 cells/well for 5-18 h before initiation of experiments. Cells were infected with adenoviral constructs in serum-free growth medium. After 4 h, virus was removed and cells incubated in complete growth medium containing 10% FBS and 5 mg/ml doxycycline to induce transgene expression. TSA pretreatments were 12-14 h. The substrate for the caspase assay was added 16-20 h after initiation of treatment/ infection and plates read 2-3 h later using a FluoStar plate reader (BMG Labtechnologies Inc., Durham, NC) with emission and excitation wavelengths of 485 and 520 nm, respectively. The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent for the CellTiter s Cell proliferation assay was added 24 h after initiation of treatment or infection and plates read at an absorbance of 490 nm 1-2 h later using the FluoStar plate reader. All treatments were performed in triplicate. Background fluorescence or absorbance was determined by incubating media with substrate alone and subtracting the values from wells containing cells. Percent cytotoxicity was calculated as follows: % cytotoxicity ¼ 1À((OD of experimental/OD of control) Â 100). The Student's t-test was used to determine statistical significance shown in Figure 7b .
Antibodies and western blot analysis Cells were plated at 7 Â 10 5 per 60 mm plate, allowed to adhere for 5-18 h, incubated in media or TSA for 12-14 h followed by infection as described above. At 24 h postinfection, cells (adherent and nonadherent, if any) were collected, pelleted, washed with PBS and lysed in RIPA buffer (1% NP-40, 0.5% deoxycholate, 0.1% SDS in PBS) containing a mammalian protease inhibitor cocktail (P-8340 Sigma). Lysates were stored at À701C and centrifuged (20 000 g) prior to performing protein assays on the supernatant (DC protein assay, BioRad, Hercules, MA). Protein (40 mg) was separated on 4-12% Bis/Tris NuPage gels in MES buffer (Invitrogen) and transferred to nitrocellulose (Bio-Rad) for 90 min at 30 V. Membranes were blocked in 5% milk in TBS-Tween for a minimum of 1 h prior to incubation with primary antibody. The monoclonal cFLIP antibody NF-6 was generously provided by Dr Marcus Peter, University of Chicago, IL. NF-6 hybridoma supernatant was used at 1:5 in TBS-Tween at room temperature overnight. The caspase-8 (Alexis), actin (Sigma), PARP (SantaCruz, Biotechnology Inc.), and TRAIL (H257, SantaCruz Biotechnology Inc.) antibodies were used at 1:2000 in 5% milk/TBS-Tween at 41C overnight. Following three washes with TBS-Tween, membranes were incubated with the anti-mouse (1:5000-50 000) or anti-rabbit (1:50 000) HRP-conjugated secondary antibodies (SantaCruz Biotechnology Inc.) for 1 h at room temperature in 5% milk/ TBS-Tween. Membranes were washed three times in TBSTween followed by chemiluminescent detection of the secondary conjugates with DuraWest Supersignal (Pierce Biotechnology Inc., Rockford, IL).
Flow cytometry
For GFP analysis, cells were plated in six-well dishes, infected for 4 h in serum-free RPMI1640, washed and incubated in complete growth medium. At 24 h postinfection, cells were trypsinized and analyzed. For surface expression of DR4, DR5, and CAR, cells were seeded overnight, removed with Cell Stripper s (Mediatech) and incubated with 10 mg/ml MOPC21 (isotype control, Sigma, St Louis, MO), anti-DR4 (Alexis, 1:100), anti-DR5 (Alexis, 1:100), or anti-CAR (clone RcmB, Upstate Biotechnology Inc., 1:500) in PBS containing 3% protease-free BSA at room temperature for 60 min. After washing in PBS, cells were incubated with PE-conjugated anti-mouse-IgG (1:250) (Biomeda Corp.) in PBS containing 3%BSA for 30 min. Cells were washed with PBS and analyzed on a FACSCalibur (Becton Dickenson, Bedford, MA) in the MUSC flow cytometry core facility. A minimum of 10 000 events was scored for each sample.
Results
and T24 bladder carcinoma cells display differential sensitivity to AdTRAIL
We have previously shown that an adenovirus, expressing TRAIL (AdTRAIL), effectively induces apoptosis in prostate cancer cell lines that are resistant to recombinant TRAIL. Since bladder cancer is an ideal target for gene therapy, we investigated the in vitro efficacy of AdTRAIL in two bladder cancer cell lines. The cell line 5637 was established from a carcinoma of a 68-year-old Caucasian male and the T24 cell line was isolated from a transitional cell carcinoma of a 81-year-old Caucasian female. Cells were infected with adenoviral constructs expressing either GFP (AdGFP, control vector) or GFP and TRAIL (AdTRAIL). 10 As shown in Figure 1 , the control virus expressing GFP caused little or no cytotoxicity (A) or caspase-3/-7 activation (B). Infection with AdTRAIL resulted in cell death and apoptosis in both cell lines but at different doses. In 5637 cells a linear response was observed with cytotoxicity becoming measurable at 3 IU/ cell. In T24 cells cytotoxicity did not become detectable until 33 IU/cell but reached levels comparable to 5637 at 111 IU/cell. Caspase-3/-7 activity also became measurable at 3 and 33 IU/cell for 5637 and T24 cells, respectively. Compared to controls caspase-3/-7 activity was increased four-fold at 11 IU/cell in 5637 cells and 333 IU/cell in T24 cells.
Susceptibility to AdTRAIL correlates with infectivity Next, we wished to examine the reason for the differential susceptibility at low virus concentrations. Initial binding of adenovirus is dependent on viral fiber protein, which binds to a receptor described as CAR. 5 Low CAR expression has been associated with poor gene transfer efficiency of recombinant adenoviral vectors. CAR expression is often decreased in bladder cancer. 12, 13 We have previously shown and confirm in Figure 2a that 5637 cells express significantly higher levels of surface CAR than T24 cells.
14 Thus the apparent lower susceptibility of T24 cells to AdTRAIL may be the result of poor infectivity.
We compared infectivity of 5637 and T24 cells by quantitating the percentage of GFP positive cells as well as GFP intensity as a measure of transgene expression following exposure to AdGFP. Cells were exposed to AdGFP for 4 h in serum-free medium, washed and incubated in growth medium containing 10% serum for 20 h. Using this protocol, 5637 cells were completely infected at 33 IU/cell (Figure 2b ). In contrast, even a 100-fold higher concentration of the virus resulted in less than 50% GFP positive T24 cells. GFP intensity was reflective of infectivity (Figure 2c) . Expression of the TRAIL transgene following infection with AdTRAIL was also examined (Figure 2d) . In 5637 cells 33 IU/cell resulted in robust TRAIL expression and activation of caspase-8. Only low amounts of TRAIL were detected in T24 cells following AdTRAIL infection (111 IU/cell), but expression was sufficient to activate caspase-8 cleavage.
The histonedeacetylase inhibitor trichostatin A restores CAR expression in T24 cells and results in protein expression reflective of a more proapoptotic phenotype Recently, it has been shown that downregulation of CAR in bladder cancer cells occurs by an epigenetic mechanism and can be restored by treatment with HDACi such as trichostatin A (TSA). 15, 16 Therefore, it was of interest to determine the effect of TSA on AdTRAIL gene therapy of T24 cells. Initially, we exposed T24 cells to increasing 
TRAIL gene therapy and HDACi
concentrations of TSA and measured cell surface CAR expression as well as infectivity using GFP as a reporter gene. CAR expression was enhanced at concentrations as low as 25 ng/ml with maximal effects seen at 50 ng/ml TSA (Figure 3a) . Restoration of CAR expression correlated well with increased infectivity (Figure 3b ) and transgene expression (not shown). As shown in Figure 3c , infection of T24 using AdGFP at 30 IU/cell results in a weak fluorescent signal whereas pretreatment with TSA resulted in bright green cells with normal adherent morphology (Figure 3d ).
HDACi have also been shown to increase sensitivity to death receptor ligands. 17 Proposed mechanisms of sensitization include upregulation of TRAIL receptors and downregulation of antiapoptotic members of the Bcl-2 family or cFLIP.
18-25 Therefore, we investigated the effect of TSA on proteins in the apoptotic pathway of T24 cells. TSA did not increase the surface expression of DR4 and DR5 (Figure 4a) . Similarly, levels of Mcl-1 and XIAP were unaffected (Figure 4b ). However, low concentrations of TSA significantly decreased the antiapoptotic proteins cFLIP (long and short isoforms) and Bcl-X L . cFLIP was maximally decreased at a concentration of 50 ng/ml TSA (Figure 4b ). Although both cFLIP isoforms decreased only cFLIP S was reduced to undetectable levels. Similar results have been obtained using antisense strategies. 26 Whether this is due to the inherent lower cFLIP S levels or reflect differences in the regulation of the isoforms remains to be determined. In contrast to cFLIP, Bcl-X L continued to decrease with increasing TSA concentrations.
TSA enhances the efficacy of AdTRAIL gene therapy in T24 cells
Next, we tested whether TSA treatment increased the efficacy of AdTRAIL gene therapy. T24 cells were pretreated with 50 ng/ml TSA followed by infection with AdGFP or AdTRAIL. In the MTS assay, TSA decreased conversion of the substrate by 20% (Figure 5a ), which was due to growth inhibition and is consistent with reports that TSA results in cell cycle arrest. 27 TSA pretreatment resulted in cell death (Figure 5a ) and caspase-3/-7 activation (Figure 5b ) following infection with low concentrations of AdTRAIL. Cytotoxicity was detectable at 3 IU/cell, and was thus comparable to 5637 cells that express high levels of CAR (see Figure 1) . In the absence of pretreatment, AdGFP or AdTRAIL induced little or no cell death and caspase-3/-7 activation. Significant caspase-8 and PARP cleavage was observed only in cells infected with AdTRAIL following TSA pretreatment ( Figure 6 ). The lack of PARP cleavage in TSA-treated cells indicates that the dose used during pretreatment was subtoxic and did not by itself induce apoptosis.
We also tested cell lysates for expression of the TRAIL transgene. In the absence of TSA, TRAIL was detected by Western blotting only after overexposure of the film (data 
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A El-Zawahry et al not shown). However, TSA pretreatment resulted in robust TRAIL expression, further confirming that increased CAR expression allows more adenoviral entry and subsequent transgene expression ( Figure 6 ).
TSA-mediated sensitization of T24 cells to TRAIL is inhibited by overexpression of cFLIP
In addition to restoring CAR expression, TSA also decreased the expression of the antiapoptotic proteins cFLIP and Bcl-X L . However, the contribution of the decrease in antiapoptotic proteins is difficult to determine following viral infection, since TSA treatment also alters the amount of TRAIL transgene expression. To eliminate the effect of TSA on CAR and viral transgene expression, we incubated TSA pretreated cells with recombinant TRAIL. We reasoned that if downregulation of cFLIP or Bcl-X L contributed to the sensitizing effect of TSA, then pretreated T24 cells should become sensitive to recombinant TRAIL. As shown in Figure 7a , pretreatment with TSA resulted in significant TRAIL-induced cell death, an effect that was greater than additive. The antiapoptotic protein cFLIP acts upstream in the extrinsic pathway of apoptosis and has been implicated by numerous studies as an important resistance factor during TRAIL-mediated cell death. [28] [29] [30] Since selective downregulation of cFLIP is sufficient for sensitization, the observation that TSA decreased this protein warranted further investigation. Two predominant isoforms of cFLIP have been described. 31 The short isoform has clearly been established to have antiapoptotic function 28, 29 but cFLIP L has also been shown to activate caspase-8 and may therefore have a proapoptotic role. 32, 33 Since TSA decreased both cFLIP L and cFLIP S , we generated T24 clones that stably overexpress either isoform as FLIP-GFP fusion proteins. 11 To rule out clonal variation, 6-9 GFP-positive clones were pooled into mass clones for each construct. From Western blot analysis it appears that there is more transgene expression in the FLIP S -GFP than the FLIP L -GFP mass clones (Figure 7b, inset) . Cells transfected with a plasmid expressing GFP only were used as a negative control. Overexpression of either cFLIP-GFP construct protected cells from TRAIL-induced cell death following TSA pretreatment while cells expressing the GFP control plasmid were not protected (Figure 7b ). The differences were statistically significant when compared to the GFP control plasmid but not between cFLIP constructs.
Discussion
Adenoviral vectors have been used for gene therapy of cancer and other malignancies but toxicity during systemic administration is a concern. 34 Since local TRAIL gene therapy and HDACi A El-Zawahry et al treatment such as intravesical therapy of superficial bladder cancer should reduce or eliminate the potential for systemic toxicity, we have examined the potential of TRAIL therapy for bladder cancer. The success of cancer gene therapy depends on several factors, including targeting and delivery as well as expression of the transgene. Decreased CAR gene expression is often observed in bladder cancer specimens 13 and would diminish the effectiveness of gene therapy using adenovirus. It has recently been shown that downregulation of CAR is mediated by histone acetylation and can be reversed by HDACi. 15, 16 We found that CAR expression in T24 cells was restored to high levels using low, nontoxic concentrations of TSA. Restoration of CAR was sufficient for high levels of transgene expression and apoptosis following exposure to low IU/ cell of AdTRAIL. This is in agreement with a recent study in which the HDACi depsipeptide enhanced CAR and transgene expression leading to increased susceptibility to Ad5-TRAIL in prostate cancer cells. 24 In addition to increasing CAR, HDACi alter the expression of various pro-and antiapoptotic proteins. In melanoma cells suberohydroxamic acid decreased XIAP, Mcl-1, and Bcl-X L while increasing expression of proapoptotic members of the Bcl-2 family and caspases. 25 Downregulation of Bcl-X L by HDACi was also demonstrated in mesothelioma cells. 22 We observed a decrease in Bcl-X L , which may contribute to sensitization by amplifying the apoptotic signal at the mitochondrial level.
HDACis also affect proteins of the extrinsic pathway of apoptosis. Several studies report increases in TRAIL receptor expression. For example, sodium butyrate and TSA selectively increase DR5 expression in colon cancer cells. 35 The HDACis LAQ824 and depsipeptide also increase TRAIL receptor expression, although abrogation of DR5 expression did not alter the sensitizing effect of depsipeptide. 19, 20 Recently it was shown that depsipeptide enhanced sensitivity to TRAIL not by increasing receptor expression but by allowing redistribution of TRAIL receptors into lipid rafts. 24 We did not detect an increase in DR4 or DR5 expression following TSA treatment but it is possible that the receptors redistributed into lipid rafts.
Expression of the antiapoptotic protein cFLIP, which binds to and inhibits caspase-8, was also downregulated by TSA. We found that both isoforms of the protein were affected equally by TSA and that overexpression of either isoform protected TSA-sensitized cells from TRAIL-induced apoptosis. Other HDACis that reduce cFLIP expression are sodium butyrate, LAQ824 and depsipeptide. 18, 19, 36 LAQ824 resulted in a isoform-specific decrease that was cell line dependent. 19 In CLL cells the short isoform of cFLIP was affected earlier and at lower concentrations of depsipeptide than the long isoform. However, downregulation of cFLIP is not consistently observed upon treatment with HDACi. 20, 23 The poor quality of some commercially available cFLIP antibodies may, in part, account for these results. 37 Our data suggest that downregulation of cFLIP is an important mechanism by which TSA sensitizes cells to TRAIL, although other mechanisms such as redistribution of TRAIL receptors and decreases in Bcl-X L may contribute to sensitization.
In summary, this study suggests that HDACi enhance efficacy of AdTRAIL gene therapy in two ways. First, HDACi can restore CAR expression thereby lowering the amount of adenovirus required for transduction of the target cells. Second, by generating a more proapoptotic phenotype, HDACi would enhance the bystander effect. TRAIL has been shown to generate a bystander effect 38 but in TRAIL resistant tumor cells a bystander effect may be difficult to achieve. Decreasing the expression of cFLIP and other antiapoptotic proteins would lower the apoptotic threshold of uninfected cells facilitating induction of apoptosis by a neighboring AdTRAIL infected cell. Several HDACis, including depsipeptide, which has been shown to decrease cFLIP expression are currently in clinical trials. 39 Combination of depsipeptide with intravesical AdTRAIL gene therapy may be an effective treatment strategy for bladder cancer.
